Fintel reports that on December 8, 2025, Needham reiterated coverage of Ocular Therapeutix (NasdaqGM:OCUL) with a Buy recommendation.
Analyst Price Forecast Suggests 81.08% Upside
As of December 6, 2025, the average one-year price target for Ocular Therapeutix is $22.78/share. The forecasts range from a low of $18.18 to a high of $32.55. The average price target represents an increase of 81.08% from its latest reported closing price of $12.58 / share.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Ocular Therapeutix is 142MM, an increase of 154.13%. The projected annual non-GAAP EPS is -0.63.
What is the Fund Sentiment?
There are 358 funds or institutions reporting positions in Ocular Therapeutix. This is an increase of 31 owner(s) or 9.48% in the last quarter. Average portfolio weight of all funds dedicated to OCUL is 0.52%, an increase of 4.21%. Total shares owned by institutions increased in the last three months by 18.32% to 197,547K shares. 
The put/call ratio of OCUL is 0.42, indicating a bullish outlook.
What are Other Shareholders Doing?
VR Adviser holds 13,161K shares representing 6.18% ownership of the company. In its prior filing, the firm reported owning 12,762K shares , representing an increase of 3.03%. The firm decreased its portfolio allocation in OCUL by 2.43% over the last quarter.
Summer Road holds 12,580K shares representing 5.90% ownership of the company. In its prior filing, the firm reported owning 13,887K shares , representing a decrease of 10.40%. The firm increased its portfolio allocation in OCUL by 0.35% over the last quarter.
Deep Track Capital holds 11,932K shares representing 5.60% ownership of the company. In its prior filing, the firm reported owning 14,294K shares , representing a decrease of 19.80%. The firm decreased its portfolio allocation in OCUL by 8.50% over the last quarter.
Avoro Capital Advisors holds 10,250K shares representing 4.81% ownership of the company. In its prior filing, the firm reported owning 7,400K shares , representing an increase of 27.80%. The firm increased its portfolio allocation in OCUL by 28.79% over the last quarter.
TCG Crossover Management holds 6,117K shares representing 2.87% ownership of the company. In its prior filing, the firm reported owning 5,319K shares , representing an increase of 13.05%. The firm decreased its portfolio allocation in OCUL by 37.61% over the last quarter.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
